Investing.comCodex · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 08:07:44·⟳ 抓取 08:09:04 +1m20s·⚡ 决策 08-28 14:39:21 +6h30m·60.1 天前
ARK披露8月27日调仓：减持Tempus AI和Twist，买入Veracyte
这是ARK每日交易披露的二手转述，核心信息是基金调仓而非上市公司经营基本面变化；买卖金额对相关公司缺少可证明的业绩或市值重估传导，且没有可用真实报价支持ENTER。
📄 原文Investing.com↗ 原文
Cathie Wood’s ARK sells Tempus AI stock, buys Veracyte
Nasdaq ends more than 1.5% higher as tech soars on Nvidia’s blockbuster earnings Cathie Wood’s ARK ETF published their…
不做 Tempus AI（TEM.US）
ARK减持不是公司级强空催化，缺少基本面净损害和可执行报价，不做空。
不做 Twist Bioscience（TWST.US）
ARK持续卖出仅为基金流向信号，不能证明Twist经营恶化，不满足做空红线。
不做 Veracyte（VCYT.US）
ARK买入金额小且非公司基本面新增利好，缺少可量化业绩增量和真实执行价。
不做 Scribe Therapeutics（SCTX.US）
ARKG买入金额过小，事件级别不足以形成独立交易机会。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件只显示ARK在2026年8月27日卖出TEM、TWST并买入VCYT、SCTX。基金日度调仓可以影响短线情绪，但不是公司收入、订单、指引、监管或资本结构变化；其中买入和卖出金额均偏小，且正文还提示为AI辅助生成的Investing.com稿件。综合看，方向更多是组合流向噪音，不具备可执行正期望。
消息传播链
- Investing.com发布ARK 8月27日交易转述，披露卖出TEM、TWST并买入VCYT、SCTX。
- 中文站同步发布同一主题，说明消息已进入公开财经资讯流。
关键理由
- ARK日度买卖只是外部基金流向，不等同于被买卖公司的基本面新增事实。
- 涉及金额最高约405.9万美元卖出TEM、333.5万美元卖出TWST、211.7万美元买入VCYT，未显示能改变公司收入、利润或市值预期。
- 消息已由Investing.com多地区页面同步扩散，缺少低扩散且可量化的交易边际。
主要风险
- 若ARK官方披露与转述不一致，应以官方每日交易文件为准。
- 未能取得stock_tools实时行情和20日轨迹，因此不能排除个别小盘标的盘前情绪波动，但这不足以构成主动交易依据。
反向证据
先例如何影响了这次决策
对本次决策的影响:先例不足与事件本身基本面含量低共同支持不做。
方向:未找到可用于定价的高相似公司级先例；基金经理日度调仓对单只股票不是稳定基本面催化。
涨幅量级:没有高相似、同市场、同机制且可锚定首发时点的样本，不能据此设定止盈止损幅度。
形态:这类披露更容易表现为短线情绪噪音或已反映的持仓流，不足以支持方向性交易。
原文全文
展开原文 · 1,822 字
Nasdaq ends more than 1.5% higher as tech soars on Nvidia’s blockbuster earnings
Cathie Wood’s ARK ETF published their daily trades for Thursday, August 27th, 2026, revealing a significant shift in their portfolio. The most notable move was the sale of 59,276 shares of Tempus AI, Inc. (NASDAQ:TEM) through its ARKK ETF, amounting to a substantial $4,059,220. This sale continues ARK’s recent trend of reducing its position in Tempus AI, following large sales earlier in the week.
In another major move, ARK sold 22,225 shares of Twist Bioscience Corporation (NASDAQ:TWST) for $3,335,083. This sale was split between the ARKK and ARKG ETFs, marking a continuation of ARK’s recent divestment from Twist Bioscience, which has been consistent throughout the week.
On the buying side, ARK acquired 47,793 shares of Veracyte, Inc. (NASDAQ:VCYT), totaling $2,116,751. The purchase was divided between the ARKK and ARKG ETFs, suggesting a strategic interest in Veracyte’s potential.
Additionally, ARK purchased 5,085 shares of Scribe Therapeutics Inc (NASDAQ:SCTX) through its ARKG ETF, with a total value of $161,194. This buy indicates an ongoing interest in the biotech sector, as seen in previous acquisitions.
Meanwhile, ARK sold smaller amounts of Roblox Corp (NYSE:RBLX) and Brera Holdings PLC (NASDAQ:SLMT). ARK offloaded 1,001 shares of Roblox for $37,597 and 29,385 shares of Brera Holdings for $116,658, continuing a pattern of consistent sales in these stocks over recent days.
These trades reflect ARK’s strategic rebalancing, focusing on biotech investments while divesting from certain technology stocks. Investors will be keen to see how these moves align with ARK’s long-term vision and market trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Cathie Wood’s ARK ETF published their daily trades for Thursday, August 27th, 2026, revealing a significant shift in their portfolio. The most notable move was the sale of 59,276 shares of Tempus AI, Inc. (NASDAQ:TEM) through its ARKK ETF, amounting to a substantial $4,059,220. This sale continues ARK’s recent trend of reducing its position in Tempus AI, following large sales earlier in the week.
In another major move, ARK sold 22,225 shares of Twist Bioscience Corporation (NASDAQ:TWST) for $3,335,083. This sale was split between the ARKK and ARKG ETFs, marking a continuation of ARK’s recent divestment from Twist Bioscience, which has been consistent throughout the week.
On the buying side, ARK acquired 47,793 shares of Veracyte, Inc. (NASDAQ:VCYT), totaling $2,116,751. The purchase was divided between the ARKK and ARKG ETFs, suggesting a strategic interest in Veracyte’s potential.
Additionally, ARK purchased 5,085 shares of Scribe Therapeutics Inc (NASDAQ:SCTX) through its ARKG ETF, with a total value of $161,194. This buy indicates an ongoing interest in the biotech sector, as seen in previous acquisitions.
Meanwhile, ARK sold smaller amounts of Roblox Corp (NYSE:RBLX) and Brera Holdings PLC (NASDAQ:SLMT). ARK offloaded 1,001 shares of Roblox for $37,597 and 29,385 shares of Brera Holdings for $116,658, continuing a pattern of consistent sales in these stocks over recent days.
These trades reflect ARK’s strategic rebalancing, focusing on biotech investments while divesting from certain technology stocks. Investors will be keen to see how these moves align with ARK’s long-term vision and market trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。